Literature DB >> 19729306

Structure-based design of novel human Pin1 inhibitors (I).

Chuangxing Guo1, Xinjun Hou, Liming Dong, Eleanor Dagostino, Samantha Greasley, Roseann Ferre, Joseph Marakovits, M Catherine Johnson, David Matthews, Barbara Mroczkowski, Hans Parge, Todd Vanarsdale, Ian Popoff, Joseph Piraino, Stephen Margosiak, James Thomson, Gerrit Los, Brion W Murray.   

Abstract

Pin1 is a member of the cis-trans peptidyl-prolyl isomerase family with potential anti-cancer therapeutic value. Here we report structure-based de novo design and optimization of novel Pin1 inhibitors. Without a viable lead from internal screenings, we designed a series of novel Pin1 inhibitors by interrogating and exploring a protein crystal structure of Pin1. The ligand efficiency of the initial concept molecule was optimized with integrated SBDD and parallel chemistry approaches, resulting in a more attractive lead series.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729306     DOI: 10.1016/j.bmcl.2009.08.034

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  26 in total

Review 1.  Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2009.

Authors:  Roland E Dolle; Bertrand Le Bourdonnec; Karin Worm; Guillermo A Morales; Craig J Thomas; Wei Zhang
Journal:  J Comb Chem       Date:  2010-10-05

2.  Epigallocatechin-gallate suppresses tumorigenesis by directly targeting Pin1.

Authors:  Darya V Urusova; Jung-Hyun Shim; Dong Joon Kim; Sung Keun Jung; Tatyana A Zykova; Andria Carper; Ann M Bode; Zigang Dong
Journal:  Cancer Prev Res (Phila)       Date:  2011-07-12

3.  Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer.

Authors:  Man-Li Luo; Chang Gong; Chun-Hau Chen; Daniel Y Lee; Hai Hu; Pengyu Huang; Yandan Yao; Wenjun Guo; Ferenc Reinhardt; Gerburg Wulf; Judy Lieberman; Xiao Zhen Zhou; Erwei Song; Kun Ping Lu
Journal:  Cancer Res       Date:  2014-05-01       Impact factor: 12.701

Review 4.  Peptidyl-Proline Isomerases (PPIases): Targets for Natural Products and Natural Product-Inspired Compounds.

Authors:  Bryan M Dunyak; Jason E Gestwicki
Journal:  J Med Chem       Date:  2016-07-25       Impact factor: 7.446

5.  A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways.

Authors:  Dayun Yang; Wensong Luo; Jichuang Wang; Min Zheng; Xin-Hua Liao; Nan Zhang; Wenxian Lu; Long Wang; Ai-Zheng Chen; Wen-Guo Wu; Hekun Liu; Shi-Bin Wang; Xiao Zhen Zhou; Kun Ping Lu
Journal:  J Control Release       Date:  2017-11-21       Impact factor: 9.776

6.  A Phosphoramidate Strategy Enables Membrane Permeability of a Non-nucleotide Inhibitor of the Prolyl Isomerase Pin1.

Authors:  Daniel M C Schwarz; Sarah K Williams; Maxwell Dillenburg; Carston R Wagner; Jason E Gestwicki
Journal:  ACS Med Chem Lett       Date:  2020-08-10       Impact factor: 4.345

7.  Pin1 protein regulates Smad protein signaling and pulmonary fibrosis.

Authors:  Zhong-Jian Shen; Ruedi K Braun; Jie Hu; Qifa Xie; Haiyan Chu; Robert B Love; Levi A Stodola; Louis A Rosenthal; Renee J Szakaly; Ronald L Sorkness; James S Malter
Journal:  J Biol Chem       Date:  2012-05-21       Impact factor: 5.157

8.  Membrane permeable cyclic peptidyl inhibitors against human Peptidylprolyl Isomerase Pin1.

Authors:  Tao Liu; Yu Liu; Hung-Ying Kao; Dehua Pei
Journal:  J Med Chem       Date:  2010-03-25       Impact factor: 7.446

9.  New Frontiers in Druggability.

Authors:  Dima Kozakov; David R Hall; Raeanne L Napoleon; Christine Yueh; Adrian Whitty; Sandor Vajda
Journal:  J Med Chem       Date:  2015-08-11       Impact factor: 7.446

Review 10.  The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target.

Authors:  Xiao Zhen Zhou; Kun Ping Lu
Journal:  Nat Rev Cancer       Date:  2016-06-03       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.